GlobeNewswire Inc | Oct 9, 2020 04:03PM EDT

October 09, 2020

EMERYVILLE, Calif., Oct. 09, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the companys board of directors granted four new employees the option to purchase an aggregate of 161,000 shares of the companys common stock, at a per share exercise price of $4.45, the closing trading price on October 7, and restricted stock units to acquire 80,500 shares of the companys common stock. The stock options and restricted stock units vest over four years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.

About Adamas Pharmaceuticals, Inc.

At Adamas our vision is clear to deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. We are a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases. For more information, please visit www.adamaspharma.com.

Contact:

Investors:Peter VozzoWestwicke Partners 443-213-0505peter.vozzo@westwicke.com

Media: Sarah MathiesonVice President, Communications & Engagement 510-450-3528smathieson@adamaspharma.com